In this way, coexpression of KIT in a high percentage of MCC suggests an important role in Merkel cell transformation [80], so that the potential use of KIT kinase inhibitor-based therapies, as imatinib, should be also considered in metastatic MCC [81, 82]. The gene discussed is KIT; the disease is Merkel cell skin cancer.